🔗 Share this article

While America continues making historic revisions to its vaccination recommendations, a particular individual has emerged somewhat surprisingly: Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on COVID-19 vaccinations throughout the pandemic and has concentrated on possible fatalities after COVID-19 vaccination in her recent time at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Vaccine Program

Agency leaders were set to announce major revisions to the childhood immunization program in December, aligning the US with Denmark’s immunization schedule, sources say – a major change that would place the US out of step with many the world with little proof for benefit. The planned update has been pushed back until the next year.

In place of Vinay Prasad, Dr. Høeg is set to speak at the meeting. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this calendar year.

A Shift at the Regulatory Body

This interim role might represent a strengthened alliance between the drug and biologics branches as Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon rolling back previously authorized vaccines at the FDA.

The new acting director has repeatedly called for discontinuing certain childhood shot schedules in the US to become more like Denmark, a society with nationalized medicine and a number of inhabitants roughly the population of the state of Wisconsin.

So far statements, she has kept her attention on vaccination policy – traditionally the domain of Prasad, head of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has little discernible experience in medication creation, oversight or administrative roles, which has been standard for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in managing a major agency. She is not an expert in drug approvals.”

Former directors of the center would “grasp legal statutes and the research of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that prior appointees who led CBER have had.”

This division has an vast range of responsibilities at the FDA, Woodcock stated.

“Everybody just zeroes in on the new drug program, but the off-patent medication office approves numerous off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and more, and all of those need to be managed,” Dr. Woodcock explained. “The area you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a significant management component to the position, which manages in excess of 5,000 employees. “It is a huge administrative position, if you do it right,” the former official said.

Official Statement and Controversial Programs

In response to questions about Dr. Høeg's fitness for the role and whether this appointment signifies increased cooperation among agency officials on vaccines, a spokesperson said that the “inquiries stem from incorrect presumptions”.

“Her experience matches the functions of her role,” the official said, citing the time Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg inherits the commissioner’s recently launched expedited review system, a controversial expedited drug-approval program that allegedly troubled her former heads. “By what process are these therapies being chosen for this voucher program? Who takes the choices?” Dr. Howard asked. “There is a lot of confidentiality occurring at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards less stringent rules of pharmaceuticals, with the exception of vaccines.”

Documented Past Work on Immunizations

With immunizations, Høeg has a more documented, if troubling, history, critics said. She authored a study using unconfirmed crowd-sourced reports to assess the frequency of myocarditis following Covid vaccination. She advised the state of Florida surgeon general Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccinations are pose a greater threat than they are.

Among her “policy goals” for the incoming federal leadership encompassed changing rules for new vaccines and halting “non-essential” vaccines, she said post-election on a online show. At the FDA, Dr. Høeg has allegedly suggested barring teenage boys from receiving Covid vaccinations.

“She’s an all-around true believer who commences with her beliefs and reverse-engineers to fit the data in a extremely deceptive, dishonest manner,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|